The low transduction efficiency of viral and nonviral vectors is a major limitation in tumour gene
Introduction
Suicide gene therapy is a promising strategy for the treatment of cancer, that involves the transfer of suicide genes into tumour cells to render them specifically sensitive to prodrugs that are relatively nontoxic to normal tissues. The most intensely studied suicide gene/prodrug combination is the herpes simplex virus type 1 (HSV-1) thymidine kinase (TK)/ganciclovir (GCV) therapy. This strategy has already been tested in clinical trials for the treatment of malignant brain tumours. [1] [2] [3] Another promising approach is the use of the bacterial enzyme cytosine deaminase (CD) with the prodrug 5-FC. 4 CD is found in many bacteria, yeast and fungi, where it deaminates cytosine to uracil. 5 It also deaminates the relatively non-toxic prodrug 5-fluorocytosine (5-FC) to the highly toxic 5-fluorouracil (5-FU), widely used in the treatment of solid malignant tumours. Transduction of the CD gene into tumour cells combined with a systemic administration of 5-FC has been shown to have anticancer effects in various animal models. [6] [7] [8] [9] [10] [11] [12] [13] Due to their inherent bystander effect toxic 5-FU metabolites also reach non-transduced neigh- 
tion immunofluorescence analysis of Ad-transduced producer cells coplated with naive cells confirmed that the characteristic foci pattern of central producer and adjoining neighbour cells displaying nuclear staining was retained. After transduction of rat hepatoma cells with adenoviral vectors and subsequent incubation with the prodrug 5-FC, we observed enhanced cell cytotoxicity when comparing the CD-VP22 fusion (Ad-CD-VP22) with Ad-vectors expressing the CD gene only (Ad-CD). Thereby employment of Ad-vectors encoding VP22 fusion proteins opens up new possibilities to potentiate the efficiency of suicide gene therapy for the treatment of solid tumours. Gene Therapy (2001) 8,

1654-1664.
bouring cells, so that gene transfer efficiencies as low as 5% are sufficient to establish significant tumour regression in some animal models. [14] [15] [16] [17] A comparison of the TK/GCV with the CD/5-FC approach in cell culture 18 and implanted tumours 19 suggested that the cytosine deaminase system might be superior, since its bystander effect does not depend on gap junctional intercellular communication channels.
However, in most cases suicide gene therapy was either not able to completely eradicate the tumours, or following the initial prodrug treatment phase the malignant cells started to grow again. 13, 16, 20, 21 Moreover, most prodrug animal experiment regimens were set to start with tumours still being very small (in the cube 1 mm 3 range). Therefore, one cannot expect that full-grown solid tumours (in the cube Ͼ1 cm 3 range) as presented in most clinical situations will be eliminated as well. Most importantly, the in vivo gene transfer efficiencies of solid tissues are still unsatisfactorily, even with adenoviral or lentiviral vectors used for transduction. Even with the highest dose of more than 10 13 adenoviral particles ever used in a clinical trial in the case of the tragic death of the patient J Gelsinger, less than 1% of the liver cells had incorporated the transgene. 22 With such low transduction rates no additive effect due to the transport of toxified prodrugs will be measurable.
In this regard, the unusual properties of HSV-1 tegu-ment protein VP22 might help to overcome low transduction rates. VP22 exhibits the remarkable capability of intercellular spread, whereby the protein is exported from the cytoplasm of expressing cells and subsequently imported into neighbouring cells where it accumulates in the nucleus. 23 VP22 fusion proteins were also found to retain this activity of intercellular protein transport, as exemplified after transfection of the fusion proteins VP22-GFP, [23] [24] [25] VP22-p53, 26 and VP22-tk. 27 Additionally, the VP22-p53 and VP22-tk fusions demonstrated enhanced therapeutic effects when compared with the unfused versions of the enzymes. 26, 27 We could show, that transport of VP22 cargo proteins is a general biological phenomenon, not restricted to distinct tissues or organs. 25 To overcome the limiting primary transduction rates of gene transfer vectors, we investigated whether chimaeric fusions, consisting of HSV-1 VP22 and E. coli CD, retain their transport property in recombinant adenoviruses and exhibit an enhanced suicide gene effect.
Results
Expression analysis of CD fusion proteins from Ad vectors
To investigate the ability of VP22 to transport the E. coli CD protein from a primary expressing cell to neighbouring recipient cells, we constructed adenoviral expression vectors for full-length in-frame CD-VP22 and VP22-CD fusion proteins, driven either by the cytomegalovirus immediate-early enhancer/promoter region or the Rous sarcoma virus long terminal repeat (LTR) promoter ( Figure 1 ). The chimaeric proteins also contain a C-ter- Gene Therapy minal epitope tag to detect full-length proteins. This CMV epitope is in-frame with the CD-VP22 fusion, but out-of-frame with the VP22-CD fusion, where it serves as an internal negative control. After transduction of COS-1 cells (at MOI 10), both adenoviral vectors (Ad-CD-VP22, Ad-VP22-CD) predominantly generated full-length fusion proteins of the expected size of 86 kDa (Figure 2 ). 26, 27 Western blot analysis was carried out using anti-VP22, anti-CD and anti-epitope antibodies (Figure 2 ). CD constructs with no VP22 fusion partner are only detected by the polyclonal CD antiserum (48 kDa; lanes 2 and 3, upper panel), with the CMV promoter producing more protein (lane 3) than its RSV counterpart (lane 2). As chimaeric constructs, consisting of VP22 and E. coli CD, driven by the RSV promoter resulted in barely detectable amounts of protein (not shown), adenoviral vectors with the RSV-LTR promoter fragment were not further evaluated in this study. With the CMV epitope placed out-offrame in the VP22-CD construct, the respective fusion protein was not detected in Western blot analysis by anti-CMV-ep antibody (Figure 2 , lower panel, lane 5), contrary to the C-terminal fusion of VP22 to CD, in which the 86 kDa fusion was recognized (CD-VP22, lower panel, lane 4).
Intercellular transport of CD fusion proteins
To determine whether the N-and C-terminal CD-VP22 and VP22-CD fusion proteins were able to spread from a primary expressing cell into neighbouring cells, we first analysed the intercellular transport function of the fusion constructs at the plasmid level. COS-1 cells were transfected by the adenoviral expression vectors and examined by indirect immunofluorescence (Figure 3 In contrast to most viral vector systems, adenoviruses are able to infect almost all cell lines due to the presence of ubiquituously expressed primary and secondary receptors. With cell lines infected at a MOI greater than 2, the transduction rate approaches 100%, so that any additive effect of VP22-mediated transport cannot be visualised. Therefore coplating experiments are required to identify spread from the VP22 producer cells to neighbouring untransduced cells. The cell lines COS-1 and CO60 can easily be detected due to their constitutive expression of the SV40 large T antigen. When mixing these cells with SV40 large T antigen naive cells of another cell type, export of VP22 fusion proteins from the adenovirus-transduced producer cells into the heterologous neighbouring indicator cells can be displayed by indirect immunofluorescence staining.
To establish the conditions for the detection of VP22- Having optimized the conditions for detecting VP22 spread after coplating, adenoviral vectors containing amino-and carboxy-terminal fusions of CD with VP22 were then examined for their property of intercellular protein transport. Figure 5 shows the results after transduction of COS-1 cells (Ad-CD, Ad-CD-VP22, Ad-VP22-CD) and subsequent mixing with naive HeLa cells in the merged presentation. All coplatings were stained with two antibodies, using anti-SV40 large T antigen to identify the COS-1 cells in all samples and a second antibody as given in Figure 5 
Quantification of CD suicide gene effect
After demonstrating that a fusion of E. coli CD with VP22 exhibits the property of intercellular protein transport subsequent to both plasmid transfection and adenoviral transduction, we set out to quantify a possible enhanced suicide gene effect by cytotoxicity assays. The SRB assay 28 is the standard assay of the US National Cancer Institute to screen for all kinds of cytotoxic substances and relies
Figure 3 VP22-mediated transport of CD fusion proteins after transfection with adenoviral expression plasmids. Upper panel, transfection with pTG6600 (negative control, no transgene) (left); 6600-CD (middle and right); middle panel, transfection with 6600-CD-VP22; lower panel, transfection with 6600-VP22-CD. COS-1 cells were transfected with 500-1000 ng expression plasmid. 40-44 h after transfection, the cells were processed for immunofluorescence and detected by different antibodies, as indicated.
on the binding of the protein dye sulforhodamin B (SRB). Based on the hepatocellular carcinoma (HCC) model of ACI rats, 29 we used syngeneic MH3924a rat hepatoma cells as targets for adenoviral transduction. Untransduced MH cells, as well as Ad-GFP transduced cells, cultured for 6 days with the same amounts of 5-FC prodrug were used as controls. Since GFP is not able to metabolize the prodrug 5-FC, no inhibition of cellular growth was detected ( Figure 5, squares) . Expression of the suicide gene CD resulted in a pronounced decline in the cell number with increasing amounts of the prodrug 5-FC. Moreover, comparing the inhibitory effect of Ad-CD with
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Ad-CD-VP22 after 6 days' incubation with 5-FC, a significantly enhanced suicide gene effect of the VP22 fusion was found for every measured value ( Figure 6 , upper panel; level of significance indicated by stars). In contrast, the N-terminal fusion of VP22 to CD did not yield an overall improved suicide effect. This finding is in full accordance with the data of our immunofluorescence studies using the VP22-CD fusion in adenoviral expression plasmids and recombinant adenoviral vectors. At the highest prodrug concentration of 10 mm 5-FC transduction of all CD constructs resulted in similar levels of CD-induced cytotoxicity. When comparing the same adenoviral constructs after 4 days' incubation with the prodrug, all measured values of the CD-VP22 fusion show a pronounced increase of the suicide gene effect, while CD and VP22-CD display nearly similar survival rates ( Figure 6, lower panel) . The concentration of 5-FC necessary to accomplish 50% inhibition of cellular growth (inhibitory concentration IC 50 ) could be reduced significantly from 2.5 mm for Ad-CD to 0.45 mm for Ad-CD-VP22 after 6 days of incubation with the prodrug.
Discussion
A major limitation for success in tumour gene therapy is the low transduction efficiency of viral and nonviral vectors. Protein transport by HSV-1 VP22 chimaeric polypeptides into up to 500 neighbouring cells offers a possible compensation for this obstacle. In a proof-ofprinciple situation, we opted to incorporate in-frame fusion genes, consisting of VP22 and E. coli cytosine deaminase (CD), into adenoviral vectors. Fusion proteins of the expected sizes were detected by Western blot analysis with the CMV enhancer/promoter fragment being the promoter of choice in this in vitro situation. However, the RSV promoter was considered to be too weak for further evaluation in spread and cytotoxicity assays. The classical verification for VP22-directed intercellular transport is by indirect immunofluorescence. Here, the amino-terminal fusion CD-VP22 showed excellent spread from the VP22 producing cells into their neighbouring cells. After plasmid transfection and adenoviral transduction, the typical foci pattern of staining was detected, with virtually all cells in the monolayer being positive for the CD-VP22 fusion protein. As adenoviral vectors usually transduce most cells under cell culture
Figure 5 Coplating of COS-1 and HeLa cells after transduction with adenoviral CD-VP22 vectors. Upper panel, uninfected cells (left), transduction with Ad-CMV-CD, MOI 50 (middle and right); middle panel, transduction with Ad-CMV-CD-VP22, MOI 50; lower panel, transduction with Ad-CMV-CD-VP22, MOI 50 (left) or Ad-CMV-VP22-CD, MOI 50 (middle and right). CO60 cells were transduced with adenoviral vectors at an MOI of 50 for 1-3 h at 37°C. 20-24 h later, the cells were trypsinised and coplated on to naive, preseeded HeLa cells at a ratio of 1:20. Immunofluorescence detection was carried out 24 h later with antibodies as indicated. Displayed in merge presentation. All coplatings were stained with two antibodies, anti-SV40 T antigen to identify the COS-1 cells in all samples plus anti-VP22 or anti-CD as second antibody.
conditions, the visualisation of VP22 spread had to be simulated by coplating transduced cells with naive, untransduced cells of a different cell type and subsequent double-staining of CD-VP22 producer cells and neighbouring indicator cells taking up the CD-VP22 fusion protein by intercellular spread. Interestingly, the carboxyterminal fusion polypeptide VP22-CD did not exhibit any transport properties. Instead, similar staining patterns as with samples of unfused monomeric CD protein were found, with only single transfected or transduced cells being positive for the transgene. So far, fusion constructs with VP22 have been described for GFP, 23 ,25,30-32 p53, 26 Gene Therapy and HSV-1 TK, 27 with most studies examining VP22 fusion protein expression following transient transfection of plasmid constructs. In these reports either only one kind of fusion construct has been analyzed, or no differences of transport efficiencies between N-and C-terminal fusions have been detected. On the other hand, it is not unexpected for biological macromolecules that connecting polypeptide chains will result in unpredictable conformations with functional domains of enzymes locating to one or the other terminus of the protein. For example, numerous fusions of GFP with proteins under investigation have been described with amino-or car- 
MH3924a cells seeded in 24-well plates were transduced with adenoviral vectors at an MOI of 20 for 3 h at 37°C. The next day, 5-FC was added in the concentrations given. After 4 days (lower panel) or 6 days (upper panel) the growth inhibition was determined by SRB staining and measured at 550 nm. All values were referred to that of the uninfected control cells and are given as percentage of surviving cells (control, 100%). All experiments were carried out at least in quadruplicate, the OD values plotted represent the mean and standard error of four replicate wells. The evaluation of the statistical significances were calculated according to the Student t test method and compares only values of Ad-CD (b) with that of Ad-CD-VP22 ( ).
boxy-terminal or both connections retaining protein function. 33 Therefore, only an empirical analysis of VP22 fusion proteins is able to elucidate which fusion products maintain the functionality of both components.
After immunohistochemical confirmation that the VP22 intercellular transport function was retained in the context of adenoviral VP22 vectors, the remaining evidence of functionality was to prove an enhanced suicide gene effect in cell death assays. The quantification of cell killing was accomplished by SRB staining, 28 which has previously been shown to be superior to MTT or clonogenic assays. Comparisons of SRB staining with the MTT enzyme assay have proven that the SRB reagent is more sensitive and detects growth inhibition with better linearity and more reliability in a greater number of cell lines than the MTT dye. [34] [35] [36] [37] We found that the amount of eradicated tumour cells after transduction with Ad-CD-VP22 was significantly higher than when using Ad-CD. The prodrug concentration necessary to eliminate 50% of the cells (IC 50 ) could be reduced by almost one log score to 0.45 mm 5-FC. This is an important finding when transferring the CD/5-FC system to the preclinical/clinical situation: high concentrations of 5-FC are metabolized in vivo by bacteria of the gut flora, so that side-effects due to the toxicity of systemic 5-FU can be expected. 38 While at the highest concentration of 5-FC similar death rates after 6 days of incubation were detected, the improved cytotoxic effect of the VP22 fusion became more substantial when using suboptimal prodrug concentrations: the CD-VP22 chimaera leads to a faster toxification (4 versus 6 days of incubation) at lower concentrations of 5-FC than conventional CD without a fusion partner. In contrast to Ad-CD-VP22, the experiments with Ad-VP22-CD did not exhibit VP22-mediated protein transport, so that the cytotoxicity assay did not show an increased suicide gene effect either.
It should be noted, that several studies have raised issues concerning the VP22 transport property. For instance it was postulated that VP22 after fixing the cells by methanol simply diffuses out of the producer cell and is taken up into the neighbouring cell due to the damage of the cell membrane, while paraformaldehyde-fixing prevents this spread effect. 39 Others concluded that methanol fixation is merely mimicking VP22-mediated protein transport. 40 This is contradicted by a report only investigating the fixation procedures of VP22 chimaeric proteins 31 together with our present analysis on quantitating a significant enhancement of the suicide gene effect. Additionally, many studies are dealing with the GFP-VP22 fusion being the only transgene tested. It is noteworthy that the fluorescence intensity of GFP in live unfixed cells is not strong enough to visualise the foci pattern of VP22 intercellular transport. 25, 30, 41 When observing GFP fluorescence of a GFP-VP22 construct in living transfected cells, only the staining patterns of the VP22 producing cells can be monitored. 42 To detect the nuclear staining of GFP-positive cells, which have taken up the fusion transgene due to VP22 transport, antibody enhancement is a necessary procedure. 23, 25 However, the yellow fluorescent protein (YFP) mutant is described to be more sensitive than GFP, so that detection of VP22 transport in live cells has been reported. 40 Moreover, the same study indicated that the transport property of the bovine herpes virus homologue of VP22 may be more effective than the HSV-1 protein.
Recent advances propose further improvements of the CD suicide gene therapy. The uracil phosphoribosyl transferase (UPRT) gene from E. coli, being an enzyme from the pyrimidine salvage pathway, catalyzes the conversion of uracil and 5Ј-phosphoribosyl-␣-pyrophosphate to UMP and is not present in mammalian genomes. When combining UPRT with the CD gene, the deamination of 5-FC to 5-FU can be augmented by the subsequent enzymatic conversion into 5-fluoro-UMP. 43 Additionally, cytosine deaminase from bakers' yeast, Saccharomyces cerevisiae (yeast CD, yCD), is reported to toxify 5-FC more efficiently than bacterial CD. 44 Joining yeast CD (FCY-1) with yeast UPRT (FUR-1) as a fusion protein is described to be even more potent in killing tumour cells. 45 We believe that the effectiveness of our VP22-modified E. coli-derived CD (bacterial CD, bCD) vectors probably can be further enhanced by a simple exchange of the E. coli-derived CD gene cassette with, for example, a yeast-derived CD gene cassette (yCD).
Combining synergistic strategies with distinct mechanisms is proposed to be most promising in antitumour therapy. Especially concomitant stimulation of the immune system by chemokines 46 or incorporation of two suicide genes, HSV-1 TK and E. coli CD, into a replicating adenovirus 47 have shown compelling success in animal models. When additionally improving the limited in vivo transduction efficiency with the help of intercellular cargo proteins, successful gene therapy of solid tumours seems feasible. At the moment, we are evaluating the property of VP22 to potentiate suicide gene therapy in the ACI rat model in vivo: syngeneic MH3924a cells implanted orthotopically in the liver develop into nonmetastatic hepatocellular carcinomas (HCC). 29 Comparing recombinant adenoviral vectors harbouring the CD-VP22 fusion gene cassette with conventional Ad-CD vectors will show whether enhanced suicide gene effects are similarly found in the in vivo situation.
Materials and methods
Adenoviral vectors
Viral genomes were constructed as infectious plasmids by homologous recombination in Escherichia coli as described by Chartier et al. 48 All vectors contain a deletion in the E1 region from nucleotide (nt) 455 to 3328. Nucleotide numbering is according to Chroboczek et al. 49 Adenoviral backbone vectors were pTG6600 and pTG8347 (Transgene, Strasbourg, France). 48 Upstream and downstream of the expression cassette these plasmids contain adenoviral sequences surrounding the deleted E1 genome region. The two recombination plasmids only differ in the promoter region (hCMV versus RSV), the intron sequence (chimaeric intron of human beta-globin splice donor and mouse IgG splice acceptor sites versus rabbit beta-globin intron), and polyadenylation sites (SV40 late polyA signal versus rabbit beta-globin polyA signal), as shown in Figure 1 .
The following suicide gene vectors and fusion constructs with VP22 were generated (Figure 1 ).
6600-CD:
The vector backbone pTG6600 was linearised with EcoRI and subsequently dephosphorylated by SAP to prevent the religation of the vector. The E. coli CD gene was isolated from pWZLneoCD 50 by EcoRI and StuI digestion. After ligation of the EcoRI sites the non-complementary ends were filled-in by treatment with Klenow enzyme, so that the resulting blunt ends could be ligated.
8347-CD:
The E. coli CD sequence was liberated by EcoRI and BamHI double digest with pCD2 51 and inserted into the pTG8347 backbone in the 'one-tube' ligation mode (details available on request).
6600-CD-VP22:
The cloning rationale of this vector involved an intermediate construct to generate suitable restriction sites in a pcDNA3 backbone (Invitrogen). Plasmid pWZLneoCDglyTK 50 was serving as a source of a full-length CD sequence for N-terminal in-frame fusions. The in-frame CD-VP22 fusion was constructed by insertion of a PCR-generated TK-VP22 fragment from ptkVP22ep 27 with synthetic restriction site linkers in the PCR Gene Therapy primers into pTG6600, and subsequent exchange of the TK with the CD coding sequence. The purification of the PCR fragments was carried out according to an optimized protocol combining distinct purification methods. 52 The resulting adenoviral recombination vector 6600-CD-VP22 contains the epitope sequence ERKTPRVTGG, which is recognised by the monoclonal antibody CMV-018-48151 (Capricorn Products, Scarborough, ME, USA). This CMV epitope sequence is derived from the phosphorylated matrix protein pp65 of hCMV (Genbank accession number M15120).
6600-VP22-CD:
The VP22-CD fusion was also generated by PCR cloning involving synthetic restriction sites in the PCR primers. The construction involved two intermediate products based on pTG6600 containing a VP22-TK fusion, as available from the plasmid pVP22-tkep. 27 The TK gene was removed and the CD fragment inserted into the same reading frame as the N-terminal VP22 sequence. However, the very C-terminal CMV epitope is no longer in-frame with the VP22-CD fusion, so that it serves as an internal control of the suicide gene-VP22 fusions.
6600-VP22:
Following removal of the TK coding sequence from the TK-VP22 cassette by BamHI digestion the vector 6600-VP22 was obtained by subsequent religation.
8347-GFP:
The GFP coding sequence was derived from pcDNA3-GFP, which was constructed by inserting the EcoRI and NotI digested GFP fragment from pEGFP-N1 (Clontech) into the equivalently cut pcDNA3 (Invitrogen) mammalian expression vector. The GFP gene was then transferred to pTG8347 by releasing the fragment by SalI digests and inserting it into compatible XhoI ends of the adenoviral vector.
Details of all cloning procedures are available on request. Ad-VP22-GFP recombinant adenovirus is a kind gift from T Harding (University of Bristol, Bristol, UK). 53 The VP22-GFP expression cassette contained in this vector was derived from pGE150. 23 Virus generation, purification and titration For the generation of recombinant adenoviruses, the respective shuttle plasmids ( Figure 1 ) were cotransformed into E. coli BJ5183, together with the pTG3602 genome plasmid. 48 The viral genomes were released from the respective recombinant plasmids by PacI digestion and transfected into the 293 complementation cell line as described previously. 48 Transfections were performed using lipofectIN (Life Technologies, Eggenstein, Germany) according the the manufacturer's protocol using 2000 ng of linearised plasmid DNA. Recombinant virus was purified using two rounds of CsCl centrifugation. Titers were determined by standard plaque assays 54 on 293 indicator cells. Plaques were scored 14 days after infection by crystal violet staining. All purified viral preparations were routinely screened for replication-competent adenoviruses (RCA) using the method of Zhang et al. 55 
Cell culture
The cell line HeLa (human cervix carcinoma) was purchased from the American Type Culture Collection (ATCC, Rockeville, MD, USA Immunofluorescence and confocal microscopy Microscopy procedures were performed essentially as described previously 23, 25 with minor modifications. In brief, cells for immunofluorescence were plated into sixwell trays at a density of 2.5 × 10 5 cells per well, each well containing one coverslip. Transfections were carried out using FuGENE 7 (Roche, Mannheim, Germany) or lipofectAMINE reagent (Life Technologies) employing 200-2000 ng of plasmid DNA. To remedy the toxicity of the lipofectAMINE lipid formulation for some cell lines (eg HeLa), medium containing double the amount of FCS was added as soon as 2 h after transfection. Cells to be processed for immunofluorescence were washed with PBS and fixed with cold 100% methanol no later than 40 h after transfection. The samples were then blocked with 10% newborn calf serum in PBS for 15 min at room temperature. Primary antibody was added in block solution and incubated for 20 min. Following two washes in PBS, incubation with secondary antibody was done for 10 min. After two more washes in PBS the coverslips were mounted in a Mowiol 40-88 (Sigma, Deisenhofen, Germany) preparation containing 2.5% DABCO as an antifade reagent. Slides were examined using a Zeiss LSM510 confocal microscope.
Coplating assay
To evaluate VP22-mediated spread after adenoviral transduction COS-1 or CO60 target cells were seeded out in six-well plates at a density of 2.5 × 10 5 cells per well. The following day adenoviral vector preparations, diluted in serum-reduced Opti-MEM medium (Life Technologies), were added at a multiplicity of infection (MOI) of 5 to 50. The transduction was carried out for 1-3 h at 37°C, then the virus-containing medium was aspirated and the cells were cultured in fresh medium. Additionally, HeLa recipient cells were seeded out as 3.0 × 10 5 cells per well in six-well plates, each well containing one coverslip. After 18-24 h the transduced VP22-producing cells were trypsinised and coplated on to the preseeded HeLa cells at a ratio of 1:20-1:100. The next day, immunofluorescence staining was performed as described above.
Western blot analysis
Transfected cell monolayers were lysed in SDS sample buffer and proteins separated by 10% SDS-PAGE and transferred to PVDF membranes as described previously. 25 Detection of reactive bands was facilitated using primary antibodies (see below) followed by horseradish peroxidase-linked secondary conjugate and ECL detection reagents according to the manufacturer's instructions (Amersham Pharmacia, Freiburg, Germany).
Antibodies
Polyclonal rabbit antiserum directed against HSV-1 VP22 (AGV30) 23 was used at a dilution of 1:500 for immunofluorescence and 1:7500 for Western blot analysis. Polyclonal rabbit anti-E. coli CD antibody 50 (a generous gift from C Richards, Glaxo-Wellcome, RTP, NC, USA) was administered at a dilution of 1:500 for immunofluorescence and 1:3000 for Western blotting. The mouse monoclonal antibody CMV-018-48151, directed against the CMV epitope, was purchased from Capricorn Products and used at a 1:100 dilution in immunohistochemistry and 1:1000 in Western blotting. For double staining in immunofluorescence mouse monoclonal anti-SV40 large T antigen antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was used at a 1:200 dilution. Secondary fluorescent antibodies for microscopy were Alexa 546 goat anti-rabbit antibody (Molecular Probes, Eugene, OR, USA; 1:200 dilution) and FITC-conjugated anti-mouse IgG (Vector, Burlingame, CA, USA; 1:100 dilution). Secondary antibodies for Western blotting were anti-mouse or anti-rabbit IgG-horseradish peroxidase conjugates at a 1:3000 dilution (Amersham Pharmacia).
SRB cytotoxicity assay
Morris hepatoma MH 3924a cells were seeded at a density of 1 × 10 4 cells/well in 24-well-plates. After 24 h 250 l of the adenoviral vector preparations were added in serum-reduced Opti-MEM medium (Life Technologies) at a MOI of 20. The transduction was carried out for 3 h at 37°C, then the virus was removed and replaced by fresh medium. The next day prodrug-containing medium was added at a concentration of 0, 0.1, 0.33, 1, 3.3 and 10 mm 5-FC (a generous gift from Roche, Basel, Switzerland). The cells were incubated for 4 to 6 days, in order to allow untreated cells to reach confluence, with a change of medium every other day. Growth inhibition was evaluated by the sulforhodamin B (SRB) assay. 28 The cells were fixed with 10% (w/v) TCA and stained with 0.4% (w/v) SRB in 1% acetic acid according to Skehan et al. 28 After solubilisation with 10 mm Tris (pH 10.5), the stained solutions were transferred to a 96-well plate for measurement in a microtiter plate reader (Dynatech MR7000, Denkendorf, Germany) using a 550 nm filter. Data plotted represent the mean and standard error of four replicate wells.
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